Taxes

Public and Private R&D are Complements, Not Substitutes

Products You May Like

Congress is hammering out the details of legislation designed to make the U.S. more competitive with China. Any package to incentivize further R&D should begin by ending the current tax penalty against it.  

While the House and Senate-passed versions of the competitiveness legislation differ, they would support American semiconductor manufacturing, increase public funding for research and development (R&D) more generally, and enact a handful of policies directed at strengthening domestic supply chains.

One welcome addition being considered is a restoration of the full deductibility of R&D expenses. As we have written before, as of this year, corporations must spread deductions for R&D costs out over 5 years, instead of taking deductions immediately. Factors like inflation reduce the value of future deductions, creating a tax penalty on R&D and disincentivizing new investment. Our economic model shows restoring full deductibility of R&D (the status quo of the U.S. tax code since at least 1954) would increase economic output and jobs for relatively low long-run fiscal cost.

Both R&D and its tax treatment matter because R&D investment drives technological change and improvement—the ultimate engine of long-run economic growth. Growth, while not everything, matters. Higher growth leads to rising living standards and human well-being.

In 2019, the U.S. invested $667 billion in R&D. The private sector is responsible for most R&D in the United States, in 2019 performing 75 percent of R&D and funding 72 percent.

Businesses Fund Majority of US Private R&D and Public R&D Investment Research and Development funding R&D funding

The National Science Foundation’s annual report on R&D further splits it into three categories. Basic research describes “experimental or theoretical work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts, without any particular application or use in view.” Applied research is also original investigation in service of acquiring new knowledge, but is “directed primarily towards a specific, practical aim or objective.” Development, meanwhile, involves applying ideas formed from research and turning them into either new products or improvements to existing products.

Each area is important. For instance, basic research is a prerequisite for the development of new products. Additionally, evidence suggests the spillover benefits of basic research spending (i.e. benefits beyond profits to the investor) are larger than the benefits of applied research, strengthening the case for supporting basic research, either directly or indirectly. At the same time, basic research discoveries generally do not improve people’s lives until applied research and development process can turn them into new useful products.

The federal government plays its most substantial role in basic research, although basic research (just over $100 billion in 2019) is a small share of total U.S. R&D. Its small share is unsurprising; despite its high social payoff in terms of increased knowledge, the likelihood of any one basic research investment yielding a profit is low. The private sector role is largest in development and applied R&D, while still comprising a third of all basic research investment in the U.S.

Public research and development and private research and development by type and funding private R&D and public R&D investment

The debate over the tax treatment of R&D comes amidst a broader debate over the importance of public and private contributions to innovation. The debate sometimes couches public and private R&D as substitutes. One example is when politicians and commentators point out the role of DARPA funding in the development of the Internet.

Pitching the two sources of R&D as substitutes is unproductive. Strong evidence indicates the social returns to R&D investment are higher than the private returns for firms, meaning government support can be highly valuable, especially when it comes to basic research.

The results of most government research, however, do not directly improve peoples’ lives. One can point to DARPA, or a variety of consumer products derived from scientific discoveries made by the space program, as a (sound!) justification for government R&D investment. But a key factor is often missing from that line of reasoning: such knowledge typically becomes productive only when private sector R&D turns it into commercial goods consumers want.

We can juxtapose that process with the way science was done in the Soviet Union. The USSR had an enormous science and technology apparatus, including a space program competitive with NASA (although, evidently, not competitive enough) that did make major achievements despite deeply repressive conditions. But USSR programs rarely produced new innovations that improved the lives of Soviet citizens. In fact, Soviet consumer goods were almost universally derided as junk. Thus, public and private R&D should not be thought of as substitutes, but rather as complements.

Turning raw science into useful technological change is where the private sector and private markets shine. Private R&D investment has major spillover benefits, too. As Yale economist William Nordhaus calculated in a famous 2004 paper on business innovation, the producers of technological innovation only capture a “miniscule fraction”—around 2.2 percent—of technological change’s social benefits. In other words, the wealth a tech entrepreneur earns from their business represents a tiny percentage of the contribution they have made to human flourishing. We have both public and private activity to thank for innovation, and it is not necessarily a zero-sum game between the two.

R&D’s large social benefits create a strong case for government support. While it should go without saying, the large social benefits of R&D provide an even stronger case against disincentivizing R&D investment, but that is exactly what current tax treatment of R&D does by requiring firms to amortize R&D expenses over five years.

Products You May Like

Articles You May Like

Home Depot’s sales are improving, but it says consumers are still cautious about spending
Rocket Lab stock pops 25% after company reports strong revenue growth, first Neutron deal
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
The 2 things that will drive the stock market after last week’s Trump-Fed rally
Space stocks saw big gains this week in part due to ‘Trump-Elon trade’ rally, analysts say

Geef een reactie